Search

everythinglearnresearchcommunity

for

Search:↓

Pumpkin seed oil is discussed as a potential treatment for hair loss, but the study cited is criticized for using a product with multiple ingredients, making it unclear if pumpkin seed oil is effective. The conversation concludes with skepticism about the study's validity and mentions that pumpkin seeds might help with DHT blocking.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.

The conversation discusses Procapil, a treatment for hair loss containing Apigenin and Oleanolic acid. Users are sharing their experiences and asking if anyone has tried it.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.